FERTIN
LIVE

Serial Number

99527265

Owner

Fertin Pharma A/S

Attorney

Tamar Niv Bessinger

Filing Date

Dec 3, 2025

Add to watchlist:

No watchlists yet
View on USPTO

FERTIN Trademark

Serial Number: 99527265

FERTIN is a trademark filed by Fertin Pharma A/S on December 3, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Fertin Pharma A/S (19 trademarks)

Industrivej 8

Entity Type: 16

Trademark Details

Filing Date

December 3, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of a wide variety of diseases and conditions, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders in chewable form, in gum form, in lozenge form, and in pouch powder form; pharmaceutical preparations for smoking cessation; aerosolized and inhaled therapeutics and pharmaceuticals for the treatment of a wide variety of diseases and conditions, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations; vitamins and dietary supplements; nicotine chewing gum for medical purposes; nicotine gum for use as an aid to stop smoking

Custom manufacturing services for pharmaceuticals and nutraceuticals; contract manufacturing services being custom manufacturing of pharmaceuticals and nutraceuticals; processing of pharmaceutical preparations being processing of medicinal plants for pharmaceutical preparations; processing of medicinal plants for nutraceutical preparations; formulation services being custom manufacture of pharmaceuticals and nutraceuticals; custom manufacture of pharmaceuticals involving blending, granulation, encapsulation, tableting, and coating of pharmaceuticals and nutraceuticals; advisory and consultancy services relating to the aforesaid

Research and development services for pharmaceuticals and nutraceuticals formulation, research, and development of pharmaceutical preparations for treatment of a wide variety of diseases and conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; formulation, research, and development of inhaled therapeutics; research, and development of pharmaceutical and well-being products being nutritional supplements for oral and intra-oral delivery systems; research, and development of pharmaceuticals for smoking cessation; provision of advice in the field of new product design; analytical testing and quality control services, namely, product quality testing services; stability testing, namely, product quality testing services involving stability of product; medical research laboratory services for pharmaceuticals and nutraceuticals; consultancy in the field of pharmaceutical and nutraceutical research; design and development of new drug delivery system products; advisory and consultancy services relating to the aforesaid

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 6, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 6, 2026 GNSL
SUSPENSION LETTER WRITTEN
Jul 6, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 1, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 1, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 1, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 5, 2026 GNRN
NON-FINAL ACTION E-MAILED
May 5, 2026 GNRT
NON-FINAL ACTION WRITTEN
May 5, 2026 CNRT
ASSIGNED TO EXAMINER
Apr 25, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 24, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 24, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Dec 3, 2025 MAFR
NEW APPLICATION ENTERED
Dec 3, 2025 NWAP